Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Nov 29;7(48):78985-78993.
doi: 10.18632/oncotarget.12587.

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Yue-Lun Zhang  1   2 , Jin-Qiu Yuan  1   2 , Kai-Feng Wang  3 , Xiao-Hong Fu  1   2 , Xiao-Ran Han  1   2 , Diane Threapleton  1 , Zu-Yao Yang  1   2 , Chen Mao  1   2 , Jin-Ling Tang  1   2
Affiliations
Meta-Analysis

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Yue-Lun Zhang et al. Oncotarget. .

Abstract

Objectives: Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all non-small cell lung cancer (NSCLC) patients and patient subgroups.

Results: A total of 456 studies were included, reporting 30,466 patients with EGFR mutation among 115,815 NSCLC patients. The overall pooled prevalence for EGFR mutations was 32.3% (95% CI 30.9% to 33.7%), ranging from 38.4% (95% CI: 36.5% to 40.3%) in China to 14.1% (95% CI: 12.7% to 15.5%) in Europe. The pooled prevalence of EGFR mutation was higher in females (females vs. males: 43.7% vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9), non-smokers (non-smokers vs. past or current smokers: 49.3% vs. 21.5%; OR: 3.7, 95% CI: 3.4 to 4.0), and patients with adenocarcinoma (adenocarcinoma vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 4.1, 95% CI: 3.6 to 4.8).

Materials and methods: PubMed, EMBASE, and the Cochrane Library were searched to June 2013. Eligible studies reported EGFR mutation prevalence and the association with at least one of the following factors: gender, smoking status and histology. Random-effects models were used to pool EGFR mutation prevalence data.

Conclusion: This study provides the exact prevalence of EGFR mutations in different countries and NSCLC patient subgroups.

Keywords: epidermal growth factor receptor; meta-analysis; non-small cell lung cancer; prevalence; systematic review.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

All authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1. The flow chart of study selection
This figure provides detailed information for the study inclusion and exclusion.
See this image and copyright information in PMC

References

    1. International Agency for Research on Cancer, World Health Organization . GLOBOCAN: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. IARC; 2014.
    1. National Comprehensive Cancer Network Non-small cell lung cancer. 2015 www.nccnorg/professionals/physician_gls/PDF/nsclpdf Accessed Apr 13, 2015.
    1. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. The Cochrane database of systematic reviews. 2010 https://www.nccnorg/professionals/physician_gls/pdf/nsclpdf CD007309. - PMC - PubMed
    1. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non–small-cell lung cancer with erlotinib or gefitinib. New England Journal of Medicine. 2011;364:947–955. - PubMed
    1. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine. 2009;361:947–957. - PubMed